SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
TEL AVIV, Israel, Aug. 01, 2023 (GLOBE NEWSWIRE) -- The new U.S. patent application is for the use of the...
TEL AVIV, Israel, Aug. 01, 2023 (GLOBE NEWSWIRE) -- The new U.S. patent application is for the use of the...
Tel Aviv, Israel / Vancouver, Canada, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE:...
Live webcast fireside chat on Monday, August 7th at 1:00 PM ETISELIN, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Outlook...
-A Phase 2a study of BAER-101 in epilepsy is planned to initiate in 2024MIAMI, Aug. 01, 2023 (GLOBE NEWSWIRE) --...
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., Aug. 01, 2023 (GLOBE...
VANCOUVER BC / ACCESSWIRE / August 1, 2023 / EMPOWER CLINICS INC. (CSE:EPW)(OTC PINK:EPWCF) ("Empower" or the "Company") announces today,...
PRINCETON, NJ / ACCESSWIRE / July 31, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical...
After the completion of local regulatory approvals, Aytu anticipates exporting to Medomie both of its novel, orally disintegrating, extended-release tablets...
Multiple Research Studies Are In Official Application Stage For EPW Curesearch Sites Covering Numerous Protocols And SpecialtiesVANCOUVER, BC / ACCESSWIRE...
SAN DIEGO and SUZHOU and SHANGHAI, China, July 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company",...
Garching / Munich, Germany and Indianapolis, IN, USA, July 31, 2023 ā Ā ITM Isotope Technologies Munich SE (ITM), a leading...
GARCHING / MUNICH, Germany and INDIANAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading...
CINCINNATI, July 31, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (āBlue Waterā or the āCompanyā) (Nasdaq: BWV), a biotechnology...
NEW YORK, July 31, 2023 (GLOBE NEWSWIRE) -- TRxADE HEALTH, Inc. (NASDAQ: MEDS) (āTRxADEā), a pharmaceutical exchange platform provider, today...
- Results Confirm that Trilaciclib Reduces Single and Multilineage Grade ā„3 Myelosuppressive Hematologic Adverse Events (HAEs) Including Neutropenia, Anemia, and...
Transaction and reduction in operating expenses enhance Mustangās cash positionWORCESTER, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc....
Patent Filing Follows Year of Preclinical Research, Academic PublicationVANCOUVER, British Columbia, July 31, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings...
Conference call to be held Tuesday, August 1, 2023, at 8:30 AM ETNEW YORK, July 31, 2023 (GLOBE NEWSWIRE) --...
Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023 Spero to receive $30...
Webinar Being Held on August 8, 2023 at 12:00 p.m. Eastern TimeSAN DIEGO, July 31, 2023 (GLOBE NEWSWIRE) -- Crinetics...